| Journal | Journal of psychiatric practice |
| Study Type | Observational Study |
| Population | Human participants |
This is the first systematic examination of medicinal cannabis use patterns among psychiatric inpatients, providing crucial real-world data on a vulnerable population where evidence remains limited. Understanding prescription patterns and associated outcomes in this cohort is essential for informing clinical decision-making and safety protocols.
This retrospective audit of 752 psychiatric inpatients in Brisbane found 4.7% had received medicinal cannabis prescriptions within 90 days prior to admission. The study examined demographics, indications, formulations, and clinical presentations associated with these prescriptions. While the prevalence appears relatively low, the study provides important baseline data on medicinal cannabis use patterns in psychiatric populations where controlled evidence remains sparse and clinical outcomes are poorly characterized.
“This audit fills a critical knowledge gap by documenting real-world medicinal cannabis use in psychiatric patients, though the 4.7% prevalence suggests either conservative prescribing or potential underreporting. The lack of outcome data limits our ability to draw clinical conclusions about efficacy or safety in this vulnerable population.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- How common is medicinal cannabis use among psychiatric inpatients?
- Should clinicians be concerned about medicinal cannabis contributing to psychiatric hospitalizations?
- What psychiatric conditions are most commonly associated with medicinal cannabis prescriptions?
- How should clinicians manage patients using medicinal cannabis during psychiatric admissions?
- Does medicinal cannabis affect length of stay in psychiatric units?
FAQ
How common is medicinal cannabis use among psychiatric inpatients?
This Australian study found that 4.7% of psychiatric inpatients (35 out of 752 patients) had been prescribed medicinal cannabis within 90 days before their hospital admission. This suggests medicinal cannabis use is relatively uncommon but present in the acute psychiatric inpatient population.
Should clinicians be concerned about medicinal cannabis contributing to psychiatric hospitalizations?
While this study demonstrates an association between recent medicinal cannabis prescriptions and psychiatric admissions, it cannot establish causation due to its observational design. Clinicians should carefully assess each patient’s cannabis use history and consider potential interactions with psychiatric conditions, but medicinal cannabis may not directly cause hospitalization.
What psychiatric conditions are most commonly associated with medicinal cannabis prescriptions?
The study does not specify which psychiatric diagnoses were most common among medicinal cannabis users in their sample. However, the research highlights the need for more evidence regarding medicinal cannabis safety and efficacy in psychiatric populations, as current evidence is limited.
How should clinicians manage patients using medicinal cannabis during psychiatric admissions?
Clinicians should obtain detailed medication histories including medicinal cannabis formulations, dosing, and timing of last use. Consider potential withdrawal effects, drug interactions with psychiatric medications, and whether continuation or discontinuation is appropriate based on individual clinical circumstances.
Does medicinal cannabis affect length of stay in psychiatric units?
While the study collected data on length of stay for patients with recent medicinal cannabis prescriptions, the specific impact on hospitalization duration is not detailed in the available summary. Further analysis would be needed to determine if medicinal cannabis use influences recovery time or discharge planning.